Insider Transactions in Q2 2025 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 04
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
2,809
-2.89%
|
$75,843
$27.2 P/Share
|
|
Jun 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,399
-2.62%
|
$244,374
$26.74 P/Share
|
|
Jun 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,955
-2.77%
|
$76,830
$26.74 P/Share
|
|
Jun 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,848
-3.71%
|
$48,048
$26.74 P/Share
|
|
Jun 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,900
-2.89%
|
$75,400
$26.74 P/Share
|
|
Jun 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,370
-3.73%
|
$139,620
$26.74 P/Share
|
|
Jun 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,505
-3.49%
|
$91,130
$26.74 P/Share
|